Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 March;59(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 March;59(1):116-20

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 March;59(1):116-20

    ORIGINAL ARTICLES

Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy

Kratochwil C. 1, Mavriopoulou E. 1, 2, Rath D. 1, Afshar-Oromieh A. 1, Apostolopoulos D. 2, Haufe S. 1, Mier W. 3, Haberkorn U. 1, Giesel F. L. 1

1 Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany;
2 Department of Nuclear Medicine, University Hospital Patras, Patras, Greece;
3 Deparment of Radiochemistry, University Hospital Heidelberg, Heidelberg, Germany

AIM: Ga-68 labeled somatostatin analogues such as 68Ga-DOTA0-Phe1-Tyr3-octrotide (DOTATOC) as PET tracers, have significantly improved the imaging of somatostatin receptors (SSTRs) expressing tumors. Due to unspecific parenchymal binding and the expression of SSTRs on leukocytes in the spleen this is the organ with the highest non-tumor uptake of DOTATOC. Therefore, we investigated the potential changes of normal tissue distribution and tumor concentration in patients with neuroendocrine tumors (NETs) with or without spleenectomy.
METHODS: Out of 420 patients with pancreatic NET undergoing 68GA-DOTATOC PET/CT eleven patients with and eleven patients without spleenectomy were derived and matched in regard to tumor histology, tumor load, age and gender. The SUVmax of liver metastases as well as of the following normal tissues was determined: pituitary gland, thyroid gland, liver parenchyma, kidneys and suprarenal glands.
RESULTS: SUVmax values with and without spleenectomy were: in the liver metastasis (19.17±6.05 versus 37.67±16.31), in the thyroid gland (2.56±1.33 versus 2.66±0.94), in the pituitary gland (4.08±1.79 versus 4.92±1.93) in suprarenal glands (7.18±3.33 versus 9.73±3.46 on the left side and 7.32±3.03 versus 11.19±5.72 on the right side), in the kidneys (8.13±4.26 on the left side and 8.11±4.16 on the right side versus 8.62±2.17 on the left side and 9.79±2.18 on the right side) and in normal liver tissue (5.74±1.55 versus 6.22±1.95). The difference was statistically significant (Wilcoxon test P<0.05) in tumor lesions, adrenal and kidney tissue.
CONCLUSION: Spleenectomy must be considered as a relevant factor when reporting the outcome of SSTR targeted diagnostics and therapies.

language: English


FULL TEXT  REPRINTS

top of page